9. Azilva

Takeda
Takeda's Azilva, marketed in the U.S. by Arbor under the brand name Edarbi, will turn in sales of $749 million in 2022, Evaluate Pharma predicted.

9. Azilva/Edarbi
Takeda/Arbor Pharma
2016 sales: $619 million

Takeda won FDA approval for blood pressure compound azilsartan, known as Edarbi, back in 2011, thumping meds like Novartis' Diovan and Daiichi Sankyo's Benicar in trials on the way to its green light.

By September 2013, though, the Japanese drugmaker had sold U.S. rights off to Atlanta-based Arbor Pharmaceuticals for an undisclosed upfront payment and the potential for milestone and royalty payments down the line.

RELATED: China's Fosun, Shanghai Pharma circle Georgia drugmaker Arbor for U.S. beef-up

On the other side of the world, though, Takeda still counts the med as a key seller in Japan, where it won approval in January 2012 as Azilva. In the drugmaker’s 2016 annual report, it listed the Azilva product family as one of four that would help it lead the Japanese pharma industry between fiscal years 2016 and 2018.

And Evaluate Pharma, for one, predicts the med will keep growing into the future. It pegs the med’s 2022 sales at $749 million.

9. Azilva

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.